**TRANSCEND WORLD (Celgene JCAR017-BCM-001)**: A phase 2, single-arm, multi-cohort, multicenter trial to determine the efficacy and safety of JCAR017 in adult subjects with aggressive B-Cell non-Hodgkin lymphoma.

The following cohorts are open:

Cohort 2:

DLBCL NOS (de novo or tFL), DHL/THL and FL3B

After 1st line (failed rituximab/antracycline)

Ineligible for HDC and HSCT (prior HSCT not allowed) due to age, performance status or comorbidity

Meeting at least, one of the following criteria:

- Age >= 70 years

- Impaired pulmonary function (DLCO <= 60%)

- Impaired cardiac function (LVEF < 50%)

- Impaired renal function (CrCl < 60 mL/min)

- Impaired hepatic function (AST/ALT > 2x ULN, bilirubin > 2 mg/dL or cirrhosis Child-Pugh B or C)

Cohort 4:

DHL/THL

Screening at initial diagnosis & apheresis prior to first line

Subjects must be eligible for anthracycline and rituximab (or other CD20-targeted agent) containing regimen as induction prior to consolidation with JCAR017

Subjects already undergoing anthracycline and rituximab containing regimen should be discussed with Medical Monitor

Subjects with CMR after 2 cycles of induction will proceed with JCAR017 infusion only at time of relapse

Cohort 5:

PCNSL

Failed first line therapy with HDCT and ASCT

no prior WBRT